COMPENSATION AND BENEFITS 15 15.1.3 COMPENSATION OF SENIOR EXECUTIVES Table 2 (AMF definition) Fiscal year ending Fiscal year ending December 31, 2016 December 31, 2017 (in euros) Due Paid Due Paid Michael Wyzga Chairman Fixed Compensation (1) 193,982 193,982 145,154 145,154 Variable Compensation — — — — Valuation of multi-year variable compensation granted in the course — — — — of the fiscal year Exceptional Compensation — — — — Directors’ Fees — — — — Benefits in kind — — — — TOTAL 193,982 193,982 145,154 145,154 Fiscal year ending Fiscal year ending December 31, 2016 December 31, 2017 (in euros) Due Paid Due Paid Bernard Gilly Chief Executive Officer Fixed Compensation 250,008 250,008 365,000 365,000 Variable Compensation (2) 125,004 75,002 127,750 125,004 Valuation of multi-year variable compensation granted in the course of — — — the fiscal year Exceptional Compensation — — — Directors’ Fees — — — Benefits in kind (3) 41,268 41,268 41,268 41,268 TOTAL 416,280 366,278 534,018 531,272 (1) Mr. Wyzga was appointed Chairman of the Board of Directors on March 2, 2016. On March 9, 2017, the Board of Directors set Mr. Wyzga’s fixed compensation at €102,500 NET for the fiscal year ended December 31, 2017. (2) On March 2, 2016, the Board of Directors of the Company awarded Mr. Gil ly a variable compensation of €75,002 as a bonus for achieving qualitative and quantitative objectives regarding the fiscal year ended December 31, 2015, mainly related to research and development programs progressing as planned. On December 1, 2016, the Board of Directors of the Company awarded Mr. Gilly a variable compensation of €125,004 as a bonus for achieving qualitative and quantitative objectives regarding the fiscal year ended December 31, 2016, mainly related to research and development programs progressing as planned, as well as to the successful IPO of the Company conducted in July 2016 on Euronext Paris. On December 19, 2017, the Board of Directors of the Company awarded Mr. Gilly a variable compensation of €127,750 as a bonus for achieving qualitative and quantitative objectives regarding the fiscal year ended December 31, 2017. It should be remembered that the payment of this variable was subject to a favorable vote at the Ordinary General Meeting held on April 12, 2018, pursuant to the “say-on-pay” regulation introduced by the Sapin 2 Law. (3) Consisting of a housing allowance. 15.2 who are affiliated with one of our significant shareholders at DIRECTORS’ COMPENSATION €300,000 as a maximum for the 2016 fiscal year and for the following fiscal years. Our Board of Directors held on March 9, Our shareholders at the mixed general shareholders’ meeting 2017 that this amount will remain unchanged for 2017. As of the held on May 19, 2016 set the total annual attendance fees to date of this Registration Document, upon recommendation of the be distributed among non-employee directors except those compensation committee, the Board of Directors sets the annual GENSIGHT BIOLOGICS – 2017 Registration Document– 157